Results 61 to 70 of about 6,369 (156)

Filgrastim [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia

Indian Journal of Medical and Paediatric Oncology, 2010
Background: The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for ...
Advani S, Achreckar Suvarna, Thomas Dennis, Krishnankutty Binny   +3 more
doaj  

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer

BMC Cancer
Background F-627 (efbemalenograstim alfa) is a novel long acting granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2) -Fc fragment with a peptide linker.
Qingyuan Zhang, Zhonghua Wang, Wei Yao, Shufang Wang, Gaochong Zhang, Jianmin Chen, Qingsong Hou, Simon Li, Hongsheng Li, Changsheng Ye, Tao Sun, Hongjian Yang, Zhendong Chen, Zhihong Wang, Xiaoan Liu, Cuizhi Geng, Xingrui Li, Jin Zhang, Hong Zheng, Zhimin Shao   +19 more
doaj   +1 more source

A clinical study of rhG-CSF of different dosages in preventing leukopenia after chemotherapy in patients with advanced non-small cell lung cancer

Zhongguo aizheng zazhi, 2015
Background and purpose: Myelosuppression is the most common dose-limiting toxicity of tumor chemotherapy in which leukocytopenia and neutropenia are the most common conditions. Not only are uptitrations of the doses of chemotherapeutic drugs limited, but
汪晓洁, 寿　涛, 胡　静
doaj  

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Clinics
OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator. METHODS: This phase III non-inferiority study
Roberto Hegg, André Mattar, João Nunes de Matos-Neto, José Luiz Pedrini, Sabina Bandeira Aleixo, Roberto Odebrecht Rocha, Renato Peixoto Cramer-Junior, Sylvie van-Eyll-Rocha   +7 more
doaj   +1 more source

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers

Drug Design, Development and Therapy, 2018
Chungam Choi,1 Byung Won Yoo,2 Choon Ok Kim,2 Taegon Hong,2 Byung Hak Jin,2 Kwang-Seok Seo,3 Ja Yun Jang,4 Min Soo Park2 1Department of Nuclear Medicine, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; 2Department of ...
Choi C, Yoo BW, Kim CO, Hong T, Jin BH, Seo KS, Jang JY, Park MS   +7 more
doaj  

Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. [PDF]

Cureus
Reddy KK, Rao SK, Saroj AK, Srivastava C, Singh TB, Palandurkar KM.   +5 more
europepmc   +1 more source